Skip to main content

Peer Review reports

From: Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition

Original Submission
28 Feb 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
7 Apr 2022 Reviewed Reviewer Report
17 Apr 2022 Reviewed Reviewer Report
13 Aug 2022 Author responded Author comments - Edna Cukierman
Resubmission - Version 3
13 Aug 2022 Submitted Manuscript version 3
4 Sep 2022 Reviewed Reviewer Report
15 Sep 2022 Reviewed Reviewer Report
19 Sep 2022 Author responded Author comments - Edna Cukierman
Resubmission - Version 4
19 Sep 2022 Submitted Manuscript version 4
1 Oct 2022 Reviewed Reviewer Report
25 Oct 2022 Reviewed Reviewer Report
8 Nov 2022 Author responded Author comments - Edna Cukierman
Resubmission - Version 5
8 Nov 2022 Submitted Manuscript version 5
Publishing
17 Nov 2022 Editorially accepted
2 Dec 2022 Article published 10.1186/s12885-022-10330-y

You can find further information about peer review here.

Back to article page